CHMP Grants Positive Opinion for KAFTRIO ® (ivacaftor/tezacaftor/elexacaftor) in Combination With KALYDECO ® (ivacaftor) in People Ages 12 and Older With Cystic Fibrosis With the Most Common Genotypes
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with KALYDECO® (ivacaftor) 150 mg to treat people with cystic fibrosis (CF) ages 12 and older with one F508del mutation and one minimal function mutation (F/MF) or two F508del mutations (F/F) in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. If approved, up to 10,000 people in Europe with CF ages 12 and older who have one F508del mutation and one minimal function mutation would be newly eligible for a medicine that targets the disease- causing protein defect. Additionally, people 12 years of age and older who have two F508del mutations and who are currently eligible for one of Vertex’s other EMA-approved cystic fibrosis medicines would be eligible for the new triple combination regimen.
The CHMP positive opinion was based on the results of two global Phase 3 studies in people with CF: a 24-week placebo-controlled study in people ages 12 years and older with one F508del mutation and one minimal function mutation and a 4-week head-to-head study of the triple combination therapy in comparison to tezacaftor/ivacaftor in people ages 12 years and older with two F508del mutations. Both Phase 3 studies showed statistically significant and clinically meaningful improvements in lung function (percent predicted forced expiratory volume in one second; ppFEV1), which was the primary endpoint, and in all key secondary endpoints. In both studies, the ivacaftor/tezacaftor/elexacaftor plus ivacaftor combination regimen was generally well tolerated.
“The clinical data for ivacaftor/tezacaftor/elexacaftor plus ivacaftor in people with CF ages 12 years and older with an F/F or F/MF genotype are unprecedented. In addition to improvements in lung function, the data have shown improvements in multiple important outcome measures, including quality of life as measured by the CFQ-R respiratory domain score,” said Professor Marcus A. Mall, M.D., Head of Department of Pediatric Pulmonology, Immunology and Critical Care Medicine at Charité University Medical Center Berlin. “Both the clinical and patient communities are excited that more people with CF will be able to benefit from CFTR modulators.”
“We are delighted to have received this positive opinion from CHMP. If approved, this would be the first CFTR modulator for people with one F508del mutation and one minimal function mutation and would bring additional benefit to people with two F508del mutations,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. “This milestone brings us one step closer to delivering this innovative CF medicine to those who are waiting, and toward our ultimate goal of providing a therapeutic option for every person with this rare and devastating disease.”
About Cystic Fibrosis
Cystic Fibrosis (CF) is a rare, life-shortening genetic disease affecting approximately 75,000 people worldwide. CF is a progressive, multi-system disease that affects the lungs, liver, GI tract, sinuses, sweat glands, pancreas and reproductive tract. CF is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF. While there are many different types of CFTR mutations that can cause the disease, the vast majority of all people with CF have at least one F508del mutation. These mutations, which can be determined by a genetic test, or genotyping test, lead to CF by creating non-working and/or too few CFTR proteins at the cell surface. The defective function and/or absence of CFTR protein results in poor flow of salt and water into and out of the cells in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus that can cause chronic lung infections and progressive lung damage in many patients that eventually leads to death. The median age of death is in the early 30s.
About KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a Combination Regimen With KALYDECO® (ivacaftor)
KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with KALYDECO® (ivacaftor) is an investigational medicine developed for the treatment of cystic fibrosis (CF) in patients ages 12 years and older who have at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KAFTRIO® is designed to increase the quantity and function of the F508del-CFTR protein at the cell surface. The EU submission for KAFTRIO® was supported by positive results of two global Phase 3 studies in people ages 12 years and older with CF: a 24-week Phase 3 study in 403 people with one F508del mutation and one minimal function mutation (F/MF) and a four-week Phase 3 study in 107 people with two F508del mutations (F/F).
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.
Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London, UK. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 10 consecutive years on Science magazine's Top Employers list and top five on the 2019 Best Employers for Diversity list by Forbes.
Special Note Regarding Forward-looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements made by Dr. Mall and Dr. Bozic in this press release, and statements regarding our expectations for the approval of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with KALYDECO® (ivacaftor) in Europe, and our expectations regarding the eligible patient population in Europe. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements. Those risks and uncertainties include, among other things, that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy or other reasons, risks related to obtaining approval for and commercializing medicines in Europe, and other risks listed under Risk Factors in Vertex's annual report and subsequent quarterly reports filed with the Securities and Exchange Commission and available through the company's website at www.vrtx.com. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.
Vertex Pharmaceuticals Incorporated
International: +44 20 3204 5275
U.S.: +1 617-341-6992
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global Expands in the Caribbean2.7.2020 15:30:00 CEST | Press release
Andersen Global announced it entered into a Collaboration Agreement with San Juan, Puerto Rico-based, full-service tax firm BDO Tax LLC, marking the organization’s debut in the region. Founded in 2000, BDO Tax LLC is led by Managing Partner Gaby Hernandez and supported by more than 140 professionals. It provides an array of tax and business advisory services to more than 3,000 clients, including transfer pricing, private client services, transaction advisory, government contracting, accounting services and tax compliance with a specific focus on international tax and inbound tax advisory. “As a former Arthur Andersen professional, I appreciate the importance and impact of working with like-minded individuals who share similar values and commitment to their clients,” Gaby said. “Collaborating with Andersen Global enhances our ability to deliver seamless coverage globally and provide a more comprehensive range of services.” “Gaby has built one of the strongest practices in the region and
Skilling lanserar MT42.7.2020 15:10:00 CEST | Pressmeddelande
Forex- och CFD-handelsplattformen Skilling nådde ytterligare en viktig milstolpe i år med integrationen och lanseringen av handelsplattformen MetaTrader 4 (MT4). Detta pressmeddelande använder multimedia. Se den fullständiga versionen här: https://www.businesswire.com/news/home/20200702005313/sv/ Skilling lanserar MT4 (Photo: Business Wire) Skilling grundades 2016 och introducerade sin egen handelsplattform 2018. I januari 2020 tillkännagav de lanseringen av branschens första sömlösa integration med Spotware cTrader. Med deras förvärv av en licens från FSA Seychellerna tidigare i år kan Skilling nu erbjuda MT4 till sina nuvarande och nya kunder på global nivå. ”Vi har arbetat outtröttligt för att lansera den berömda MetaTrader 4, även känd som MT4, den elektroniska handelsplattformen som allmänt används av investerare runt om i världen. Idag är vi stolta över att äntligen kunna erbjuda våra kunder en mycket anpassningsbar plattform med många avancerade verktyg och funktioner, till exem
Zynga Closes Transformational Acquisition of Istanbul-based Peak; Expands Forever Franchise Portfolio with Toon Blast and Toy Blast2.7.2020 15:05:00 CEST | Press release
Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, and Peak, Istanbul-based creator of Toon Blast and Toy Blast, announced today that the companies have closed the transaction under which Zynga acquired all of the issued and outstanding common shares of Peak for a total purchase price of approximately $1.85 billion comprised approximately of equal contributions of cash and Zynga common stock. Peak brings to Zynga a renowned, talented team and two forever franchises, Toon Blast and Toy Blast, that have consistently ranked within the top 10 and top 20 U.S. iPhone grossing games for the past two years, respectively. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200702005008/en/ Zynga Closes Transformational Acquisition of Istanbul-based Peak; Expands Forever Franchise Portfolio with Toon Blast and Toy Blast (Graphic: Business Wire) Peak will continue to be led by founder and Chief Executive Officer Sidar
Smiths Detection launches iCMORE algorithms for lithium batteries and dangerous goods for HI-SCAN 10080 XCT2.7.2020 11:00:00 CEST | Press release
Smiths Detection, a leading detection and security company, has launched iCMORE detection algorithms for lithium batteries and dangerous goods for use by its HI-SCAN 10080 XCT scanner, becoming its first explosive-detection system (EDS) to offer these options. The algorithms enhance the scanner’s detection capabilities by helping identify lithium batteries, flammable liquids and solids, and compressed and liquefied gasses, which can pose a risk should they ignite or explode. With iCMORE, Smiths Detection can now reliably and accurately detect potentially dangerous lithium batteries, alongside other dangerous goods, across both its conventional X-ray and its EDS technologies. The iCMORE lithium batteries and dangerous goods algorithms are complementary adaptions to existing screening technology. Although the screening of dangerous goods is not yet mandatory in hold-baggage and air-cargo screening, the increased level of safety for passengers, staff and assets is a key driver for the imp
EUSA Pharma Announces FDA Approval of Phase 3 Clinical Trial for Siltuximab in Hospitalized Patients With COVID-19 Associated Acute Respiratory Distress Syndrome2.7.2020 10:00:00 CEST | Press release
EUSA Pharma, a global biopharmaceutical company focused on oncology and rare disease, today announced that the U.S. Food & Drug Administration (FDA) has approved a randomized, double-blind, placebo-controlled Phase 3 clinical trial protocol to evaluate the safety and efficacy of intravenous siltuximab plus standard of care in hospitalized patients with COVID-19 associated Acute Respiratory Distress Syndrome (ARDS). Siltuximab is a monoclonal antibody that directly neutralizes interleukin (IL)-6, an inflammatory cytokine detected at elevated levels in multiple inflammatory conditions, including COVID-19. It specifically binds to IL-6, thereby inactivating IL-6 induced signalling. Lee Morley, Chief Executive Officer, EUSA Pharma, said:“Since the start of the pandemic, a growing body of evidence has been published highlighting that COVID-19 associated ARDS may exhibit features of systemic hyperinflammation, resulting from excessive cytokine production – the so-called ‘cytokine storm’ – wi
Deenova Multiplies its Pharmacy Automation Market Presence into 7 European Countries2.7.2020 09:34:00 CEST | Press release
Deenova reported today its 2020 step-by-step but relentless continued geographic expansion into Austria, Belgium, France, Germany, Portugal, Spain, and Switzerland, with three new and seasoned business development staff totaling 66 years of healthcare industry experience. Christophe Jaffuel, Deenova’s International Business Development Director, stated: “I am extremely pleased to add Carlos Duran (formerly from Becton Dickinson-Carefusion-Rowa), Thierry Geraud (previously from Becton Dickinson-Carefusion-Pyxis) and Hilmi Sunay (recently from Omnicell-Health Robotics and Arxium-IHS Riva) to an already strong Deenova sales team. These 3 extremely talented and experienced individuals joined Deenova because of its unique technology and business approach to R.O.I., and total service solutions proven in the health care industry. I was equally impressed with Deenova’s demonstrated results when I joined the company 6 months ago, witnessing first-hand how Deenova simultaneously improves patient
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom